Ibogaine microdosing in a patient with bipolar depression: a case report

Fernandes-Nascimento, Maria Helha; Viana-Ferreira, Karine; Chaves, Bruno Daniel Rasmussen; Negrão, André Brooking; Wang, Yuan‐Pang

doi:10.47626/1516-4446-2021-2359

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ibogaine ( 162 , Figure B) is an indole alkaloid and a psychedelic substance that can be isolated from the root bark of an African shrub . It was reported to be useful for the treatment of substance use disorders with long-enduring effects, and a promising drug candidate for the treatment of bipolar depression and other psychiatric disorders. , However, the therapeutic effects of ibogaine are accompanied by hallucinogenic effects and potential cardiovascular toxicity, with the latter likely due to its inhibition of the hERG potassium channel . Recently, Cameron et al reported the design and synthesis of ibogaine analogues with simplified structures and improved therapeutic potential through a function-oriented synthesis strategy .…”

Section: Chemical Classifications and Structure–activity Relationship...mentioning

confidence: 99%

Serotonin 2A Receptor (5-HT_2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Duan,

Cao,

Wang

et al. 2023

Chem. Rev.

View full text Add to dashboard Cite

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic effects by activating the serotonin 2A receptor (5-HT 2A R). Clinical trials have demonstrated the traditional psychedelic substances like psilocybin as a class of rapid-acting and long-lasting antidepressants. However, there is a pressing need for rationally designed 5-HT 2A R agonists that possess optimal pharmacological profiles in order to fully reveal the therapeutic potential of these agonists and identify safer drug candidates devoid of hallucinogenic effects. This Perspective provides an overview of the structure−activity relationships of existing 5-HT 2A R agonists based on their chemical classifications and discusses recent advancements in understanding their molecular pharmacology at a structural level. The encouraging clinical outcomes of psychedelics in depression treatment have sparked drug discovery endeavors aimed at developing novel 5-HT 2A R agonists with improved subtype selectivity and signaling bias properties, which could serve as safer and potentially nonhallucinogenic antidepressants. These efforts can be significantly expedited through the utilization of structure-based methods and functional selectivity-directed screening.

show abstract

Section: Chemical Classifications and Structure–activity Relationship...mentioning

confidence: 99%

Serotonin 2A Receptor (5-HT_2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Duan,

Cao,

Wang

et al. 2023

Chem. Rev.

View full text Add to dashboard Cite

show abstract

“…In recent years, along with the growing use of psychedelics in the treatment of psychiatric disorders, research about the therapeutic effects of ibogaine has begun to take its first steps in this direction. For example, Fernandes-Nascimento et al (2022) recently reported a single case study of ibogaine microdosing for the treatment of type II bipolar disorder (BPD) [ 78 ]. Microdosing, a growing trend in the psychedelics field, is defined as recurrent administration of small doses of psychedelic drugs, with little to no identifiable acute drug effects, with the intention of improving mental health and general wellbeing, enhance cognitive performances and boost mood [ 79 , 80 ].…”

Section: Tabernanthe Ibogamentioning

confidence: 99%

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Mastinu

Anyanwu

Carone

et al. 2023

IJMS

View full text Add to dashboard Cite

The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics. For several years there has been growing interest among psychotherapists in psilocybin or lysergic acid diethylamide for the treatment of obsessive-compulsive disorder, of depression, or of post-traumatic stress disorder, although results are not always clear and definitive. In fact, the mechanisms of action of psychedelics are not yet fully understood and some molecular aspects have yet to be well defined. Thus, this review aims to summarize the ethnobotanical uses of the best-known psychedelic plants and the pharmacological mechanisms of the main active ingredients they contain. Furthermore, an up-to-date overview of structural and computational studies performed to evaluate the affinity and binding modes to biologically relevant receptors of ibogaine, mescaline, N,N-dimethyltryptamine, psilocin, and lysergic acid diethylamide is presented. Finally, the most recent clinical studies evaluating the efficacy of psychedelic molecules in some psychiatric disorders are discussed and compared with drugs already used in therapy.

show abstract

Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis

Fernandes-Nascimento,

Negrão,

Viana-Ferreira

et al. 2023

Journal of Psychoactive Drugs

View full text Add to dashboard Cite

Ibogaine microdosing in a patient with bipolar depression: a case report

Cited by 3 publications

References 4 publications

Serotonin 2A Receptor (5-HT_2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Serotonin 2A Receptor (5-HT_2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis

Contact Info

Product

Resources

About

Ibogaine microdosing in a patient with bipolar depression: a case report

Cited by 3 publications

References 4 publications

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis

Contact Info

Product

Resources

About

Serotonin 2A Receptor (5-HT_2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Serotonin 2A Receptor (5-HT_2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants